The medtech industry remains on the upswing as companies see their stocks rising with quarterly earnings providing a boost. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 30) at 118.86 points. Two weeks ago aside — when the index shot up to 145.88 points […]
Dexcom
Dexcom beats Street — but remains coy on U.S. G7 launch
Dexcom (NSDQ:DXCM) shares are up more than 13% today — a day after Q2 results that topped the consensus forecast. The San Diego-based continuous glucose monitor developer also announced continued clinical and regulatory progress with its next-gen G7, though the timing of a U.S. G7 release is still an open question. Dexcom posted profits of […]
MedTech 100 roundup: Return to normal after last week’s spike
After rising more than 31 points to heights never before reached, the medtech industry returned to normal this past week. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 23) at 115.54 points, a total that, had it not been for the previous week, would […]
Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
As we enter what may be the “new normal,” Dexcom’s CEO bets the company can pave the way in continuous glucose monitoring. Dexcom (NSDQ:DXCM), like any company seeking to innovate, remains in a state of perpetual forward motion. That’s the way chair, president & CEO Kevin Sayer views it, anyway. As the company looks toward the […]
FDA clears Dexcom Partner Web APIs
Dexcom (NSDQ:DXCM) announced today that it received FDA clearance for its Dexcom Partner Web application programming interfaces (APIs). The San Diego–based company’s Dexcom Partner Web APIs enable invited third-party developers to integrate real-time continuous glucose monitoring (CGM) data into their digital health apps and devices. Get the full story at our sister site, Drug Delivery Business […]
Dexcom touts CGM studies, shares data on next-gen G7
Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). Get the full story at our sister site, Drug Delivery Business News.
Study shows CGMs better at controlling blood sugar in type 2 diabetes
Kaiser Permanente is touting a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes. Patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia, the study found. The study was […]
Barclays is bullish on medtech
A Barclays analysis projects that medtech might be on its way to a stretch of “outperformance” even in the wake of the COVID-19 pandemic. According to SeekingAlpha, the report cited eight reasons that make the investment bank bullish on the industry in the coming years, starting with what it calls “robust innovation.” On top of […]
Lilly partners with four companies on insulin pen tech
Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with Lilly’s latest insulin pen. The Tempo Pen is a modified version of Lilly’s existing prefilled, disposable insulin pen to which the Tempo Smart Button — in late-stage development – attaches. Through these new agreements, the Tempo Smart Button will […]
MedTech 100 roundup: Return to normal following recent spike
After back-to-back all-time best performances, the medtech industry had a slight regression over the course of the last week. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — had been continuously ticking up since the beginning of April, with its mark of 112.25 on April 16 representing an all-time […]
Dexcom dips after hours despite Street-beating Q1, raised guidance
Dexcom (NSDQ:DXCM) shares took a hit after hours today despite first-quarter results that beat the consensus forecast. DXCM shares were down -5.2% at $400 per share after hours. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%. Get the full story at our sister site, Drug Delivery Business […]
